The estimated Net Worth of Raymond F Schinazi is at least $82.3 Milhão dollars as of 4 May 2021. Raymond Schinazi owns over 575,000 units of Precision BioSciences stock worth over $80,587,080 and over the last 10 years Raymond sold DTIL stock worth over $1,696,250.
Raymond has made over 7 trades of the Precision BioSciences stock since 2015, according to the Form 4 filled with the SEC. Most recently Raymond sold 575,000 units of DTIL stock worth $1,696,250 on 4 May 2021.
The largest trade Raymond's ever made was buying 4,878,050 units of Precision BioSciences stock on 1 September 2016 worth over $2,000,001. On average, Raymond trades about 728,745 units every 116 days since 2014. As of 4 May 2021 Raymond still owns at least 7,674,960 units of Precision BioSciences stock.
You can see the complete history of Raymond Schinazi stock trades at the bottom of the page.
Raymond's mailing address filed with the SEC is C/O PRECISION BIOSCIENCES, INC., 302 E. PETTIGREW STREET, SUITE A-100, DURHAM, NC, 27701.
Over the last 6 years, insiders at Precision BioSciences have traded over $352,500 worth of Precision BioSciences stock and bought 224,670 units worth $1,909,002 . The most active insiders traders include Raymond F Schinazi, Llc Fmr, eMichael Amoroso. On average, Precision BioSciences executives and independent directors trade stock every 22 days with the average trade being worth of $357,735. The most recent stock trade was executed by Dario Scimeca on 7 June 2024, trading 301 units of DTIL stock currently worth $3,161.
Precision BioSciences, Inc., a clinical stage gene editing company, develops vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which a specific type of immune cell, called a T cell, is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Precision BioSciences executives and other stock owners filed with the SEC include: